Dow Chemical has poured money into lobbying efforts over the last decade as other corporate giants have remained steady or even pulled back on their spending.
Lobbying expenditures by the company nearly tripled between 2008 and 2016, according to a Bloomberg BNA review of disclosure filings, from $5.2 million to $13.5 million annually.
The company is in the process of seeking Justice Department approval for a $79 billion merger with Dupont Co.
Collectively, companies involved in agrichemical mergers—Dow, Dupont, Bayer AG, Monsanto Co., and Syngenta AG—spent $1.6 million more in the first quarter of 2017 over the same period last year, and 2.7 times the expenditures for the first quarter of 2008.
A look at Dow’s year-on-year quarterly spending is even more impressive: resources for lobbying jumped nearly eightfold in the first quarter of 2017 compared to the first quarter of 2008. At $5.2 million, Dow is the seventh-biggest spender on lobbying for the first quarter of 2017, as revealed in forms filed with the Senate April 20.
The filings also show that Dow hired a lobbying firm to meet with members of Congress on issues before the Agriculture Department and the EPA weeks before an agency deadline to act on the insecticide chlorpyrifos, which is widely used on fruits and vegetables and was developed by the company. EPA denied to restrict the pesticide on March 29.
The merger with Dupont is just one of multiple concerns the company is raising with policymakers. While the merger has dominated the company’s priorities more recently, it’s probably not the biggest reason for the growth in lobbying spending, said Alex Vogel, co-founder of the VogelHood Group, a Washington, D.C. public affairs firm. Regulatory pressures, and high-stakes bills like last year’s reform of the Toxic Substances Control Act, are more likely drivers than the upcoming merger decision, he said.
“There are numerous justifications for them to be more engaged in addition to the merger,” Vogel told Bloomberg BNA.
An apparent close relationship to President Donald Trump’s administration—CEO Andrew Liveris was appointed to head a White House manufacturing council and donated $1 million to Trump’s inauguration—also has raised questions over the company’s influence in government.
Liveris “has extraordinary access in the White House, chairs a group that advises Mr. Trump, was there when Mr. Trump signed his executive order relating to cutting back regulation,” Norm Eisen, a fellow with the Brookings Institution and former adviser to President Barack Obama on government ethics, said in a recent interview on PBS NewsHour. “It doesn’t smell right.”
Financially, the company can afford it. Dow reported $888 million in net income for the first quarter of 2017 in its April 27 earnings statement, more than five times the amount reported for the same period last year.
Dow tends to front-load its lobbying spending early in the year to cover trade association dues, said Rachelle Schikorra, associate director for Dow’s public affairs. Dow paid $4.8 million in 2015 to the American Chemistry Council and the U.S. Chamber of Commerce, and other groups in dues.
“Historically, our first and second quarter reports . . . are higher than subsequent quarters throughout the year,” Schikorra told Bloomberg BNA in an email.
Dow Chemical and DowAgroSciences began combining their respective filings in 2014—a year in which spending records show an increase to $14.4 million from $10.7 million over the previous year. This boosted the collective number attributed to advocacy despite an overlap in activities, said Schikorra.
Compared to Dow, many of the top spenders in 2008 have significantly pulled back on their spending. ExxonMobil, which spent $29 million in 2008, has decreased its spending about 10 percent per year since, and Pacific Gas & Electric Corp. cut its lobbying budget by about 25 percent per year, according to an analysis prepared by VogelHood.
Dow’s spending stands out. Other companies planning agrichemical mergers—which include biotechnology units that produce genetically-engineered seeds—have either remained steady or fluctuated in the last decade.
Spending for Bayer—which is planning a $66 billion buyout of Monsanto—has zigzagged between $4.2 million and $8.3 million per year since 2008. Dupont’s spending peaked in 2014 at $10.2 million—up from $4.2 million in 2008—but has since dipped back down to $5.5 million. Monsanto’s lobbying expenditures have dropped by half, from $8.8 million in 2008 to $4.6 million last year. Syngenta, which is planning to merge with ChemChina, has kept its lobbying spending around $1 million per year during that period.
As congressional gridlock intensified during the Obama administration, many companies—seeing their priorities lost in the bickering—shed their lobbying contracts. The Trump administration’s anti-regulatory focus is likely to reinvigorate interest in lobbying said Tyson Slocum, who oversees federal policy related to commodity markets as director of the nonprofit Public Citizen’s Energy Program.
But more spending doesn’t necessarily mean smooth sailing, Slocum warned. For example, CEO Liveris has come out against increasing exports of liquefied natural gas, a move that would raise domestic prices for the industrial chemical feedstock. But the Trump administration has taken the opposite tack, with Energy Secretary Rick Perry and top economic adviser Gary Cohn backing plans to build LNG export terminals.
“You are absolutely going to see spikes” in spending with the new administration, Slocum told Bloomberg BNA. But “right now, I don’t know what kind of returns they are going to see.”
Dow Agrosciences was one of three firms to hire lobbyists on environmental policy in the last few months.
Cornerstone Government Affairs is representing Dow’s seed-and-pesticide branch in meetings with members of Congress on reforming the Endangered Species Act and the Federal Insecticide, Fungicide and Rodenticide Act, pollinator protection, USDA biotechnology programs, and the EPA’s pesticide risk assessments. Cornerstone—which has several clients tied to farming, forestry and ranching—assigned four lobbyists to these issues and spent $20,000.
Dow achieved a significant regulatory victory last month when EPA Administrator Scott Pruitt announced that it would not grant environmentalists’ petition to ban nearly all uses of chlorpyrifos, a broad spectrum and widely used insecticide. Pruitt reversed the Obama administration’s plan to restrict the insecticide due to its association with neurodevelopmental delays in children, which is largely based on studies that Dow views as weak. The green groups have challenged Pruitt’s decision in the U.S. Court of Appeals for the Ninth Circuit ( Pesticide Action Network N. Am. v. EPA, 9th Cir., 14-72794, 4/5/17 ).
“Dow’s lobbying spending aligns to strategic areas of focus for the company which can vary from year to year,” spokeswoman Schikorra said.
Cornerstone began lobbying for Dow on March 15, according to its registration form, two weeks before the EPA denied the petition. On April 13, Dow and two other pesticide manufacturers asked Cabinet members to re-evaluate scientific findings on protecting endangered species from insecticides, including chlorpyrifos.
Environmental advocates criticized the company’s perceived sway in the new administration when news of the letter emerged on April 20.
“When you look at the amount of money that Dow puts into lobbying and donations to politicians and how adamantly they oppose reasonable restrictions, wouldn’t that money be better spent dealing with the underlying issue?” Center for Biological Diversity government affairs director Brett Hartl told Bloomberg BNA. “Instead of just lobbying to prevent the status quo, why don’t you just do the right thing?”
Syngenta also deployed lobbyists from Squire Patton Boggs LLC to meet with members of Congress on the regulatory framework for pesticides, Endangered Species Act reform and conservation. The EPA is currently conducting a review of Syngenta’s atrazine herbicide and has said it will submit the ecological risk assessment to a panel of outside scientists for peer review later this year. Since the herbicide was last registered in 2003, several new studies have been published on its environmental and health effects.
Monsanto hired SBL Strategies partner and former Sen. James Inhofe (R-Okla.) staffer Chad Bradley to lobby Congress on environmental policy. Monsanto is pushing for a swift re-registration of glyphosate, the main ingredient in its Roundup weedkiller, as it fights back a European finding in 2015 that the herbicide probably causes cancer.
California recently announced that it would list glyphosate as a carcinogen under its Proposition 65 law, which requires labeling of substances known to cause cancer or create reproductive problems. Monsanto is challenging the decision in the state’s Court of Appeals ( Monsanto v. OEHHA, Cal. Super. Ct., 16CECG00183, 3/22/17 ).
“In one way or another, we are all connected to agriculture and the hard work of farmers,” said Monsanto spokeswoman Charla Lord in an email, when asked about the renewed focus on environmental policy.
“Our level of engagement is similar to that of other companies of our size,” Lord added. “We want to ensure legislators are aware of modern agriculture, digital tools for agriculture and the latest innovations that are important to farmers.”
Syngenta spokesman Paul Minehart said the decision to hire Squire Patton Boggs on environmental issues did not reflect a growing focus on environmental regulations.
“We regularly assess our advocacy resources and revise as needed,” he said in an email. “Providing information on federal environmental regulations is key for US grower productivity and competitiveness, and we support environmental policy that is science-based, meets grower needs and protects our environment.”
To contact the reporter on this story: Tiffany Stecker in Washington, D.C. at email@example.com
To contact the editor responsible for this story: Paul Connolly at PConnolly@bna.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)